Kyntra Bio
KYNB
96 hedge funds and large institutions have $593M invested in Kyntra Bio in 2015 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 53 increasing their positions, 8 reducing their positions, and 10 closing their positions.
563% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 8
200% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 10
26% more funds holding
Funds holding: 76 → 96 (+20)
19% more capital invested
Capital invested by funds: $500M → $593M (+$92.9M)
11% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $1.46M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$31.2M |
| 3 |
JP Morgan Chase
New York
|
+$26.1M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$21M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sculptor Capital
New York
|
-$41.4M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$37.7M |
| 3 |
PC
PointState Capital
New York
|
-$22.1M |
| 4 |
Goldman Sachs
New York
|
-$7.92M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.76M |
KYNB Hedge Fund Activity: Q2 2015 in Review
96 of the 3,729 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2015, worth a combined $593M — up 19% from $500M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new KYNB positions and 10 closed out — a net gain of 20 holders — while 53 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $46.2M. The largest seller was Sculptor Capital, exiting entirely with an estimated $41.4M sold.
- 96 institutional investors held Kyntra Bio (KYNB) as of Q2 2015, up from 76 in Q1 2015.
- Funds reported $593M of Kyntra Bio stock for Q2 2015, up 19% quarter-over-quarter.
- 30 funds opened new Kyntra Bio positions in Q2 2015 and 10 closed out, a net change of +20 holders.
- The largest Kyntra Bio buyer in Q2 2015 was Vanguard Group, an estimated $46.2M added.
- The largest Kyntra Bio seller in Q2 2015 was Sculptor Capital, an estimated $41.4M sold.
Based on aggregated 13F filings for Q2 2015.